The CHMP adopted a positive opinion for Vueway® (gadopiclenol) for its use in pediatric patients under 2 years of age
PR Newswire —
The benefit-risk ratio of Vueway® considered positive in children from birth MILAN, Dec. 19, 2025 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces that on 11 December 2025 the Committee for Medicinal Products for Human Use (CHMP) of the European...